Dear Doctor - Participate in the Survey on thromboprophylaxis " A recent survey of patients with thrombophilia found that most patients are not receiving adequate thromboprophylaxis. Thrombophilia is a condition that predisposes patients to developing blood clots, and thromboprophylaxis is the use of medication or other interventions to prevent blood clots from forming.The survey found that only 43% of patients with thrombophilia were receiving anticoagulant medication, which is the most effective form of thromboprophylaxis. This means that the majority of patients with thrombophilia are not being adequately protected from developing blood clots.There are several reasons why patients with thrombophilia may not be receiving appropriate thromboprophylaxis. First, many patients are not aware that they have thrombophilia. Second, even when patients are aware of their condition, they may not be aware of the importance of using anticoagulants or other forms of thromboprophylaxis. Third, some patients may be reluctant to take anticoagulants because of the potential side effects. Finally, some physicians may not be familiar with the latest guidelines for managing thrombophilia and therefore may not be prescribing anticoagulants to their patients with this condition.The results of this survey underscore the need for better education for both patients and physicians about thrombophilia . Participate in Surveys "
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Review looks at potential treatment targets in the tumor microenvironment.
3.
Even when they are not paying attention, children are still learning.
4.
The Benefits of Exercise for Substance Use Disorders.
5.
The top three drugs for multiple myeloma treatment upfront are four.
1.
The New Era of Oncology: Key Updates and Clinical Insights
2.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
3.
Decoding Granular Cell Tumor: What You Need to Know
4.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
5.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Navigating the Complexities of Ph Negative ALL - Part XI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation